>
Aprea Therapeutics Inc logo

APRE - Aprea Therapeutics Inc Share Price

$4.65 0.3  7.6%

Last Trade - 16/04/21

Sector
Healthcare
Size
Small Cap
Market Cap £71.2m
Enterprise Value £6.87m
Revenue £n/a
Position in Universe 5156th / 6850
Bullish
Bearish
Unlock APRE Revenue
Momentum
Relative Strength (%)
1m -26.4%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -88.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000 0.59
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, ApreaTherapeutics Inc revenues was not reported. Net lossincreased 91% to $53.5M. Higher net loss reflects Researchand development increase of 81% to $37.9M (expense),General and administrative increase of 74% to $14.9M(expense), Foreign currency (loss) gain decrease from $1.3M(income) to $890K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

APRE Revenue Unlock APRE Revenue

Net Income

APRE Net Income Unlock APRE Revenue

Normalised EPS

APRE Normalised EPS Unlock APRE Revenue

PE Ratio Range

APRE PE Ratio Range Unlock APRE Revenue

Dividend Yield Range

APRE Dividend Yield Range Unlock APRE Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
APRE EPS Forecasts Unlock APRE Revenue
Profile Summary

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate, APR-246, is a small molecule p53 reactivator that is being developed for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). APR-246 product candidate is designed to be administered intravenously and forms the active moiety, 2-methylene-quinuclidin-3-one (MQ), under physiological conditions. Its second product candidate, APR-548, is a p53 reactivator. APR-548 is being developed in an oral dosage form.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated May 3, 2019
Public Since October 3, 2019
No. of Shareholders: 28
No. of Employees: 17
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 21,186,827
Free Float (0.0%)
Eligible for
ISAs
SIPPs
APRE Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for APRE
Upcoming Events for APRE
Thursday 22nd April, 2021
Aprea Therapeutics Inc R&D Update - Corporate Call
Friday 25th June, 2021 Estimate
Aprea Therapeutics Inc Annual Shareholders Meeting
Frequently Asked Questions for Aprea Therapeutics Inc
What is the Aprea Therapeutics Inc share price?

As of 16/04/21, shares in Aprea Therapeutics Inc are trading at $4.65, giving the company a market capitalisation of £71.2m. This share price information is delayed by 15 minutes.

How has the Aprea Therapeutics Inc share price performed this year?

Shares in Aprea Therapeutics Inc are currently trading at $4.65 and the price has moved by -86.34% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Aprea Therapeutics Inc price has moved by -90.58% over the past year.

What are the analyst and broker recommendations for Aprea Therapeutics Inc?

There are no analysts currently covering Aprea Therapeutics Inc.

When will Aprea Therapeutics Inc next release its financial results?

Aprea Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Aprea Therapeutics Inc dividend yield?

Aprea Therapeutics Inc does not currently pay a dividend.

Does Aprea Therapeutics Inc pay a dividend?

Aprea Therapeutics Inc does not currently pay a dividend.

When does Aprea Therapeutics Inc next pay dividends?

Aprea Therapeutics Inc does not currently pay a dividend.

How do I buy Aprea Therapeutics Inc shares?

To buy shares in Aprea Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Aprea Therapeutics Inc?

Shares in Aprea Therapeutics Inc are currently trading at $4.65, giving the company a market capitalisation of £71.2m.

Where are Aprea Therapeutics Inc shares listed? Where are Aprea Therapeutics Inc shares listed?

Here are the trading details for Aprea Therapeutics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: APRE
What kind of share is Aprea Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Aprea Therapeutics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Aprea Therapeutics Inc share price forecast 2021?

Shares in Aprea Therapeutics Inc are currently priced at $4.65. At that level they are trading at 61.29% discount to the analyst consensus target price of 0.00.

Analysts covering Aprea Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.844 for the next financial year.

How can I tell whether the Aprea Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aprea Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -84.11%. At the current price of $4.65, shares in Aprea Therapeutics Inc are trading at -75.01% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Aprea Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Aprea Therapeutics Inc.

Who are the key directors of Aprea Therapeutics Inc?

Aprea Therapeutics Inc's management team is headed by:

Christian Schade - CHM
Lars Abrahmsen - SVP
Johan Christenson - IND
John Henneman - LED
Eyal Attar - SVP
Scott Coiante - CFO
Gregory Korbel - VBD
Gregory Wessels - OTH
Richard Peters - DRC
Fouad Namouni - DRC
Michael Kelly - DRC
Who are the major shareholders of Aprea Therapeutics Inc?

Here are the top five shareholders of Aprea Therapeutics Inc based on the size of their shareholding:

Karolinska Development AB Corporation
Percentage owned: 11.54% (2.44m shares)
HealthCap AB Venture Capital
Percentage owned: 11.17% (2.37m shares)
KDev Investments AB Individual Investor
Percentage owned: 8.4% (1.78m shares)
Versant Ventures Venture Capital
Percentage owned: 6.73% (1.43m shares)
Redmile Group, LLC Investment Advisor/Hedge Fund
Percentage owned: 5.99% (1.27m shares)
Similar to APRE
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.